Overview on coinfection of HTLV-1 and tuberculosis: Mini-review

Masoud Keikha a, b, Mohsen Karbalaei c, *

a Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
b Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
c Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran

ABSTRACT

Human T-cell leukemia virus type 1 (HTLV-1) is one of the human retroviruses that causes various complications in humans, including lymphoma. Mycobacterium tuberculosis (Mtb), on the other hand, is a causative agent of tuberculosis (TB), a deadly infectious disease. According to the literature, patients infected with HTLV-1 are prone to TB due to lack of regulation in the immune system. In the present study, we discussed the association between previous HTLV-1 infection and TB susceptibility. We also reviewed the histopathological findings of respiratory involvement following HTLV-1 infection and the management of this infection.

1. Introduction

Among infectious diseases, tuberculosis (TB) is one of the ten leading causes of death in the world. According to the World Health Organization (WHO) report, in 2019 there were about 10 million cases of TB and 1.2 million deaths among HIV-negative people [1]. Overall, one-third of the world’s population is infected with Mycobacterium tuberculosis (Mtb) as latent TB infection (LTBI) cases [2]. Although most LTBI patients have no clinical symptoms during their lifetime, about 5–10% of them will progress to active TB [3].

After Mtb enters the lungs, four categories are predictable for its fate including: 1) immediate clearance of Mtb from lungs, 2) active TB caused by replication of tubercle bacilli in the human’s body, 3) LTBI which is characterized by the formation of granulomas due to immune-response to prevent bacteria from replicating and spreading in the body, 4) reactivation of LTBI that occurs during decreased immune response activity (Fig. 1) [4,5].

2. Progression of LTBI to active TB

2.1. LTBI phase

LTBI is a specific stage of infection that shows the balance between the microbe and the host immune response. In the LTBI phase, intracellular growth of Mtb is reduced by immune cells especially Th1, Th17, CTLs, B cells, as well as cytokines such as IFN-γ, TGF-β or IL-1β [6,7]. Depending on the host epigenetic events, excessive secretion of cytokines such as IFN-γ, TNF-α, and IL-1β can cause tissue damage resulting in active proliferation of Mtb [8,9].

2.2. Predisposing factors for the activation of latent TB

Progression of TB from the states of latent phase mode to active TB is more common among the patients with underlying conditions such as cancer, diabetes, immunodeficiency, transplantation, as well as in patients infected with viruses such as HIV or HTLV-1 [10]. Studies show that dysregulation of the immune response in HTLV-1-infected patients is considered a hallmark for LTBI progressing to active TB infection; during infection with the virus, T regulatory (T reg) cells increase, while Mtb inhibitory cell lines such as Mucosal-associated invariant T (MAIT) cells and Invariant natural killer T (iNKT) cells decrease [11–15].

3. Coinfection of TB and HTLV-1

3.1. HTLV-1

HTLV-1 was first identified by Poiesz et al. in a patient with cutaneous T cell lymphoma (CTCL) in the United States [16]. HTLV-1 is a type C Retrovirus (Deltaretrovirus) and is prevalent in various regions including Japan, Africa, Latin America, the Caribbean, and the Middle East, especially Iran [17]. Approximately 5–10 million people worldwide are infected with HTLV-1; of these 90–95% of infected persons live...
asymptomatic carriers (ACs), but 2–6% of them develop to Adult T-cell leukemia/lymphoma (ATLL) as well as 2–3% progress to HTLV-1-associated myelopatony/tropical spastic paraparesis (HAM/TSP) [18]. HTLV-1 is transmitted in a variety of ways such as unsafe sexual contact, injection, blood transfusion, congenital, and breastfeeding [19].

3.2. HTLV-1 and TB

HTLV-1 is a successful intracellular pathogens that provides persistent infection due to its ability to attack the immune response. Several strategies for persistent HTLV-1 infection include; I) inhibition of IRF3 by SOCS1, II) clonal proliferation of T reg cells, III) over-expression of surface molecules (e.g. FasL, KIR2DL2, CADM1 or CCL22), and IV) infection of CD4 + T cells [20]. In addition, HTLV-1 is transmitted throughout cell–cell contacts and causes a variety of disorders during the course of infection including uveitis, infective dermatitis, arthritis, lymphadenitis, polymyositis, Sjogren syndrome, and bronchiolitis [20,21]. In general, it seems that the previous HTLV-1 infection may make the host susceptible to infectious diseases such as TB [14]. Based on the evidence in the present study, we discussed the role of HTLV-1 infection in the pathogenesis of Mtb.

3.3. Global statistics about the TB and HTLV-1 coinfection

According to Grassi et al. study, there is a significant relationship between co-infection with HTLV-1 and Mtb in areas where these infectious pathogens are endemic. They showed that the incidence of TB in patients with HTLV-1 was 3.3 per 1000 cases, while the incidence of TB in healthy individuals was 1.1 per 1000 cases [14]. In another study, Pedral-Sampaio et al. reported that 8.5% of HTLV-1-infected patients were also infected with TB [22]. In their study, Bastos et al. reported that 10% of TB patients were also infected with HTLV-1 [23].

Studies show that people infected with HTLV-1 are also unable to produce TNF-α, so they are more likely to develop TB [23]. Verdonck et al. showed that TB mortality was higher in HTLV-1 infected individuals than in healthy ones [24]. Based on studies, the immune response to Mtb antigens is suppressed in these patients; in accordance with this theory, Tachibana et al. found that the Mantoux test was negative in asymptomatic HTLV-1 individuals [25]. Moreover, Mascarenhas et al. have shown that Polymorphonuclear leukocytes (PMNs) of HTLV-1-infected individuals were unable to migrate to the PPD injection site [26]. It is suggested that the HTLV-1 infection can cause a 2–4-fold increase in progression to TB infection [27].

3.4. Immunological characteristics in HTLV-1 infection

HTLV-1 infection leads to activation of CD4 + T cells, resulting in spontaneous lymph proliferation and overexpression of cytokines; HAM/TSP patients have high levels of proinflammatory cytokines such as IL-4, IL-6, IL-8, IFN-γ, MIP1α, TNF-α, as well as in ATLL patients the expression of IL-2, TGF-β, IL13, IL-15 leads to activation of NF-kB signaling pathway [28,29]. Moreover, Souza et al. confirmed that there was a significant overexpression of IFNγ/IL-10 and TNF/IL-10 ratios in HAM/TSP patients with TB compared to non-TB patients [30]. However, it is not yet clear how HTLV-1-infected individuals are susceptible to Mtb, whereas there is overexpression of cytokines in their activated T cells.

In general, there are several immunologic events in HTLV-1-infected people that increase their susceptibility to TB including; 1) impairment of TNF-α production, 2) impairment of IL-1β and IL-17 production, 3) increasing in the number of T reg cells 4) overexpression of TGF-β production, 5) malfunction of HTLV-1-infected lymphocytes (Fig. 2/Table 1) [28–33].

3.5. TB in facing with all features of HTLV-1

Kawahata et al. showed that HTLV-1 was isolated from Bronchoalveolar lavage (BAL) samples specimens in HTLV-1-infected individuals (HAM/TSP and asymptomatic carriers) [31]. Clinical findings showed that the total number of pulmonary lymphocytes (Th1, CTLs, and T reg cells) is higher in these patients than healthy individuals [32,33]. Teruya et al. observed overexpression of ICAM-1, cytokines (IL-1α, IL-1, IL-6, IL-8, and TNF), and chemokines (MIP-1α, IP-10, CCL2, and CCL5) in PMNs of HTLV-1-infected cases with pulmonary complications [34]. Therefore, we conclude that HTLV-1 can alter the nature of pulmonary involvement, especially in TB pathogenesis (Table 1) [33–35].

Fig. 1. Different outcomes of tuberculosis infection. This figure is inferred from Khademi et al. study.
In addition, chest radiographic findings show similarities in the histopathological features of lung infection in both HTLV-1 and 
*M. tuberculosi*s pathogens. According to related studies, these histopathological damages include parenchymal destruction, lymphatic infiltration, centriflobular nodules, bronchovascular patches, irregular linear opacities, cavity, and bronchiectasis [33,36,37].

Almost 40 years after the discovery of the virus, there is no effective and selective treatment for HTLV-1 infections [6,40]. Currently, one of the major concerns about HTLV-1 infection is the lack of selective anti-HTLV-1 drugs [18]. Typically, HTLV-1-infected patients are treated with zidovudine (AZT) plus IFN-α [41]. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) against HTLV-1 include zidovudine, (AZT), emtricitabine (FTC), didanosine (ddI), lamivudine (3TC), stavudine (d4T), abacavir (ABC), zalcitabine (ddC), and tenofovir (TDF); because rifampin interferes with NRTIs, it is not recommended for cases of retrovirus infection [18,42]. Therefore, the management or treatment of pulmonary TB in patients infected with HTLV-1 is associated with many challenges. Therefore, it is necessary to establish programs to control HTLV-1 infections, such as screening blood products for HTLV-1, preventing breastfeeding of HTLV-1-infected mothers, and safe sexual contact [43].

**4. Conclusion**

TB is a predictable disease among people infected with HTLV-1, and the main study during clinical trials should be conducted in developing countries where the prevalence of both infections is high. Importantly, this coinfection can be associated with high mortality. Therefore, careful monitoring, especially in cases of negative PPD, should be considered as prevention with isoniazid. However, the best solutions to this problem should be low cost and possible for TB in endemic areas.

**Ethical statement**

This manuscript is a mini review, and based on scientific databases such as Google Scholar, PubMed, Scopus, etc.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

[1] Organization WH. Global tuberculosis report 2020. Global tuberculosis report 2020.

---

**Table 1**

Possible mechanisms for TB among –1-infected subjects.

| HTLV-1 infection | Immune-response | Significant change | TB outcome          | Computed tomography                          | Ref |
|------------------|-----------------|--------------------|---------------------|----------------------------------------------|-----|
| HAM/TSPs         | IFN-γ, IL-2, IL-12, IP-10 and MIP-1α and CTLs | Exaggerate immune-response and damage tissue | Active TB | Granuloma formation, Cavitation, irregular linear opacity, centriflobular nodules | [34] |
| ATLLs            | IL-10, TGF-β and CD25 + T regulatory cells | Suppression of immune-response against TB | Miliary TB | Varies from cavitation to no visible symptoms | [38] |
| ACs              | TNF-α, IL-1β, Th17 and Th17 | No significant symptoms, and dependent on epigenetic events | Active TB/Latent TB | Granuloma formation, nodular patch | [39] |
Pedral-Sampaio DB, Martins NE, Pedrosa C, Brites C, Duarte M, Harrington Jr W, Bangham CRM. Human T cell leukemia virus type 1: persistence and pathogenesis. Bertazzoni U, Ciminale V, Romanelli MG. Molecular pathology of HTLV-1. Soltani A, Hashemy SI, Zahedi Avval F, Soleimani A, Rafatpanah H, Rezaee SA, Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and Keikha M, Shabani M, Navid S, Sadegh Ehdaei B, Karbalaei Zadeh Babaki M. What Montes M, Sanchez C, Verdonck J, Lake JE, Gonzalez E, Lopez G, et al. Regulatory T cell expansion in HTLV-I and strongyloidiasis co-infection is associated with Marino-Merlo F, Balestrieri E, Matteucci C, Mastino A, Grelli S, Macchi B. Starling ALB, Coelho-dos-Reis JGA, Peruhype-Magalhaes V, Dias SA, Pinto G, Araujo MG, Pinheiro SR, Guedes AC, et al. Molecular targeting for treatment of human T lymphotropic virus type I infection. Biomed Pharmacother 2019;109:770-8, Keikha M, Soleimanpour S, Eslami M, Yousefi B, Karbalaei M. The mystery of tuberculosis infection. Clin Dev Immunol 2011;2011:1. Carvalho NB, de Lourdes Bastos M, Souza AS, Neto EM, Arruda S, Santos SB, et al. Impaired TNF- IL-1beta, and IL-17 production and increased susceptibility to Mycobacterium tuberculosis infection in HTLV-I infected individuals. Tuberculosis 2018;98:35-40, Futch N, Prates G, Mahieux R, Casse J, Dutrarte H. Cytokine networks dysregulation during HTLV-I infection and associated diseases. Viruses 2018;10(12):18691. Yamagishi M, Watanabe T. Molecular hallmarks of adult T cell leukemia. Front Microbiol 2012;3:334, Souza A, Carvalho N, Neves Y, Braga Santos S, Bastos MDL, Arruda S, et al. Association of tuberculosis status with neurologic disease and immune response in HTLV-I infection. AIDS Res Hum Retroviruses 2017;33(11):1126-33, Kavabata T, Higashimoto I, Takashima H, Izumo S, Kubota R. Human T lymphotropic virus type I (HTLV-I)-specific CD8+ cells: accumulation in the lungs of patients infected with HTLV-I with pulmonary involvement. J Med Virol 2012;84(7):1120-7, Sugimoto M, Nakashima H, Watanabe S, Uyama E, Tanaka F, Ando M, et al. T lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 1987;330(8569):1220. https://doi.org/10.1016/S0140-6736(87)9363-6, Díaz A, Falcão LF, Falcão AS, Normando VM, Quaresma JA. Human T lymphotropic virus I pulmonary and diseases. Front Microbiol 2019;10:1879, Teruya H, Tomita M, Senba M, Ishikawa C, Tamayose M, Miyazato A, et al. Human T-cell leukemia virus type I infects human lung epithelial cells and induces gene expression of cytokines, chemokines and cell adhesion molecules. Retrovirology 2008;5(1):86. https://doi.org/10.1186/1742-4690-5-86, de Lourdes BM, Osterbauer B, Mesquita DL, Carrera CA, Albuquerque MJ, Silva L, et al. Prevalence of human T-cell lymphotropic virus type I infection in hospitalized patients with tuberculosis. Int J Tuberc Lung Dis 2006;10(12):1519-23, Tatedeni U, Nishihara H, Miyasaka K. HTLV-I-associated bronchopneumonopathy (HAB): CT-pathological correlation. Clin Radiol 2001;56(8):664-6, Honarbaksh S, Taylor GP. High prevalence of bronchiolitis is linked to HTLV-I-associated inflammatory disease. BMC Infect Dis 2015:15:208, Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005;24(39):6047-57, Starling ALB, Coelho-dos-Reis JGA, Peruhype-Magalhaes V, Pascoal-Xavier MA, Gonçalves DU, Béla SB, et al. Immunological signature of the different clinical stages of the HTLV-I infection: establishing serum biomarkers for HTLV-I-associated disease morbidity. Biomarkers 2015;20(6):702-12, Tagaya Y. A-109 A novel multi-cytokine inhibitory strategy in treating HTLV-I diseases. JAIDS J Acquired Immun Def Syndromes 2019;81:35, Marino-Merlo F, Balestrieri E, Matteucci C, Mastino A, Grelli S, Macchi B. Antiretroviral therapy in HTLV-I Infection: an updated overview. Pathogens 2020;9(3):342. https://doi.org/10.3390/pathogens9030342, Pedral-Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, Badaro R. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis Official Publ Braz Soc Infect Dis 1997;1:31, Bastos MDL, Santos SB, Souza A, Finkmoore B, Bispo O, Barreto T, et al. Influence of HTLV-I on the clinical, microbiologic and immunologic presentation of tuberculosis. BMC Infect Dis 2012;12:181, https://doi.org/10.1186/1471-2334-12-189, Verdonck K, Gonzalez E, Henrotroza G, Nabeta P, Llanos F, Conejo H, et al. HTLV-I infection is frequent among out-patients with pulmonary tuberculosis in northern Lima, Peru. Int J Tuberc Lung Dis 2007;11:1166-72, Tachibana N, Okayama A, Ishizaki J, Yokota T, Shishime E, Muri K, et al. Suppression of tuberculosis skin reaction in healthy HTLV-I carriers from Japan. Int J Cancer 1988;42(6):829-31, Mascarenhas RE, Brodklyn Claudia, Barbosa G, Clairencio J, Andrade-Filho AS, Figueiras F, et al. Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type I have a reduced capacity to respond to recall antigens. Clin Vaccine Immunol 2006;13(5):547-52, Carvalho NB, de Lourdes Bastos M, Souza AS, Neto EM, Arruda S, Santos SB, et al. Impact on interferon-alpha treatment on clinical and immunovirological aspects of HTLV-I infection. JAIDS J Acquired Immun Def Syndromes 2015;70(1):69-71, ao LF, Ribeiro MA, Barbosa G, Clare-Mendes V, Pascoal-Xavier MA, Gonçalves DU, Béla SB, et al. T-reg cells in children with human T-lymphotropic virus 1 infection: potential clinical implications. PLoS One 2017;12:e0173545, Grassi MFR, dos Santos NP, Lirio M, Kritski AL, Chagas Almeida MdC, Santos LP, et al. Tuberculosis incidence in a cohort of individuals infected with human T-lymphotropic virus type 1 (HTLV-I) in Salvador, Brazil. BMC Infect Dis 2016;16(1). https://doi.org/10.1186/s12879-016-1428-z, Keikha M, Shabani M, Navid S, Sadegh Ehdaei B, Karbalaei Zadeh Babaki M. What is the role of T reg cells in tuberculosis pathogenesis? Ind J Tubercology 2018;65(4):360-2, Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci 1980;77(12):7415-9, Rafatpanah H, Rezaee A, Etemadi MM, Hosseini BF, Khorram B, Afshar L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-I-associated myelopathy in northeast of Iran. J Neuroinmunol 2012;250(1-2):87-90, Soltani A, Hashemy SI, Zahedi Avval F, Soleimani A, Rafatpanah H, Rezaee SA, et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother 2019;109:770-8, Bertazzoni LI, Gimelvaz V, Romanelli MG. Molecular pathology of HTLV-I. Front Microbiol 2018;9:3069, Bangham CRM. Human T cell leukemia virus type I: persistence and pathogenesis. Annu Rev Immunol 2018;36(1):43-71, Gross C, Thomas-Kress A. Molecular mechanisms of HTLV-I cell-to-cell transmission. Viruses 2016;8(3):74. https://doi.org/10.3390/v8030074, Pedral-Sampaio DB, Martins NE, Pedrosa C, Brites C, Duarte M, Harrington Jr W. Co-infection of tuberculosis and HIV/HIV retroviruses: frequency and prognosis among patients admitted in a Brazilian Hospital. Braz J Infect Dis Official Publ Braz Soc Infect Dis 1997;1:31.